Increased expression of c-rel, from the NF-κB/Rel family, in T cells from patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 27, Issue 1, 2000, Pages 116-127

  Burgos, Patricia ^a   Metz, Claudia ^a   Bull, Paulina ^a   Pincheira, Roxana ^a   Massardo, Loreto ^a   Errázuriz, Carolina ^a   Bono, María Rosa ^b   Jacobelli, Sergio ^a   González, Alfonso ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

Autoimmunity; c rel; NF B REL; Systemic lupus erythematosus

Indexed keywords

CHLOROQUINE; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; METHYLPREDNISOLONE; PREDNISONE; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUPUS ERYTHEMATOSUS; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; CHILD; CONCANAVALIN A; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-REL; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0033969317     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Baeuerle PA, Baltimore D. NF-KB: ten years after. Cell 1996; 87:13-20.
2. Liou H-C, Baltimore D. Regulation of the NF-KB/Rel transcription factor and 1KB inhibitor system. Curr Opin Cell Biol 1993; 5:477-87.
3. Baldwin AS. The NF-KB and IKB proteins; new discoveries and insights. Annu Rev Immunol 1996;14:649-81.
4. Barnes PJ. Karin M. Nuclear factor-KB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
5. Baeuerle PA. Henkel K. Function and activation of NF-KB in the immune system. Annu Rev Immunol 1994;12:141-79.
6. Köntgen F, Grumont RJ, Strasser A. et al. Mice kicking the c-rel prolo-oncogene exhihit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995; 9:1965-77.
7. Liou HC, Sha WC. Scott ML, Baltimore D. Sequential induction of NF-KB/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-59.
8. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by NF-KB. Trends Cell Biol 1998;8:107-11.
9. Sundsledt A, Sigvardsson M, Leanderson T, Hedlund G, Kalland T. Dohlsten M. In vivo anergized CD4+ T cells express perturbed API- and NF-KB transcription factors. Proc Natl Acad Sci USA 1996;93:979-84.
10. Wang W. Tam WF, Hughes CCW, Rath S, Sen R. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 1997;6:165-74.
11. Steinberg AD. NIH conference. Systemic lupus erythematosus. Ann Intern Med 1991;115:548-59.
12. Hahn BH, An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erylhematosus. Philadelphia: Lea & Febiger; 1996;67-70.
13. Dayal AK, Kammer GM. The T cell enigma in lupus. Arthritis Rheum 1996;39:23-33.
14. Kammer GM, Khan IU, Malemud CJ. Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 1994;94:422-30.
15. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995;155:2269-81.
16. Tsokos GC. Biochemical and molecular abnormalities in the pathogenesis of systemic lupus erythematosus. Clin Exp Rheumatol 1991;9:533-9.
17. Cohen PL. T and B cell abnormalities in systemic lupus. J Invest Dermatol 1993;100 Suppl:69S-72S.
18. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-KB in human inflamed synovial tissue. Arthritis Rheum 1996,39:583-91.
19. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-KB in rheumatoid synovium. Arthritis Rheum 1995;38:1762-70.
20. Becker H, Slengl G, Stein M, Federlin K. Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases. Clin Exp Immunol 1995;99:325-30.
21. Venkataraman L, Wang W, Sen R. Differential regulation of c-Rel translocation in activated B and T cells. J Immunol 1996; 157:1149-55.
22. Venkataraman L, Burakoff SJ, Sen R. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 1995;181:1091-9.
23. Kalli K, Huntoon C, Bell M, McKean DJ. Mechanism for T cell antigen receptor and CD28 or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-KB. Mol Cell Biol 1998;18:3140-8.
24. Bryan RG, Li Y, Lai JH, Van M, Rice N. Effect of CD28 signal transducton on c-Rel in human peripheral blood T cells. Mol Cell Biol 1994;14:7933-42.
25. Lai J-H, Tan T-H. CD28 signaling causes a sustained down-regulation of lKBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994;269:30077-80.
26. Harhaj EW, Maggirwar SB, Good L, Sun S-C. CD28 mediates a potent costimulatory signal for rapid degradation lKBβ which is associated with accelerated activation of various NF-KB/Rel heterodimers. Mol Cell Biol 1996;16:6736-43.
27. Tan EM, Cohen AS, Fries JS, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Bombardier C, Gladman DD, Urowitz MB. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
29. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
30. Brownell E, O'Brien SJ, Nash WG, Rice N. Genetic characterization of human c-rel sequences. Mol Cell Biol 1985;5:2826-31.
31. Bull P, Hunter T. Verma IM. Transcriptional induction of the murine c-rel gene with serum and phorbol-12-myristate-13-acetate in fibroblasts. Mol Cell Biol 1989;9:5239-43.
32. Schreiber E, Matthias P. Müller M. Schaffner W. Rapid detection of octamer binding proteins with mini-extracts prepared from a small number of cells. Nucl Acids Res 1989;17:6419.
33. Ausubel FM, Brent R. Kingston RE, et al. Current protocols in molecular biology. Vol. 1-3. New York: John Wiley & Sons: 1995.
34. Kinoshita T, Imamura J, Nagai H. Shimotohno K. Quantification of gene expression over a wide range by the polymerase chain reaction. Anal Biochem 1992;206:231-5.
35. Dukas K, Sarfati P. Vaysse N, Pradayrol L. Quantitation of changes in the expression of multiple genes by simultaneous polymerase chain reaction. Anal Biochem 1993;215:66-72.
36. 2+ and reactive oxygen intermediates as messengers. FEBS Lett 1996;392:129-36.
37. Grumont RJ, Gerondakis S. The murine c-rel proto-oncogene encodes two mRNAs, the expression of which is modulated by lymphoid stimuli. Oncogene Res 1990;5:245-54.
38. Brownell E, Mathieson B. Young HA, Keller J, Ihle JN, Rice NR. Detection of c-rel related transcripts in mouse hematopoietic tissues, fractionated lymphocyte populations, and cell lines. Mol Cell Biol 1987;7:1304-9.
39. Crispin JC, Alcocer-Varela J. Inlerleukin-2 and systemic lupus erythematosus - fifteen years later. Lupus 1998;7:214-22.
40. Miyamoto S, Chiao PJ, Verma JM. Enhanced IKB-α degradation is responsible for constitutive NF-KB activity in mature murine B-cell lines. Mol Cell Biol 1994;14:3276-82.
41. Grumont RJ, Gerondakis S. Murine c-rel transcription is rapidly induced in T-cells and fibroblasts by mitogenic agents and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Cell Growth Differ 1990;1:345-50.
42. Hannink M. Temin HM. Structure and autoregulation of the c-rel promoter. Oncogene 1990;5:1843-50.
43. Grumont RJ, Richardson IM, Gaff C, Gerondakis S. rel/NF-KB nuclear complexes that bind KB sites in the murine c-rel promoter are required for constitutive c-rel transcription in B cells. Cell Growth Differ 1993;4:731-43.
44. Chu Z-L, McKinsey TA. Liu L. Qi X, Ballard DW. Basal phosphorylation of the PEST domain in IKBβ regulates its functional interaction with the c-rel proto-oncogen product. Mol Cell Biol 1996;16:5974-84.
45. Whiteside ST, Epinat J-C, Rice NR, Israël A. l kappa B epsilon, a novel member of the IKB family, controls ReIA and cRel NF-KB activity. EMBO J 1997;16:1413-26.
46. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IKB-β regulates the persistent response in a biphasic activation of NF-KB. Cell 1995;80:573-82.
47. Weil R, Laurent-Winter C, Israel A. Regulation of IKBβ degradation. Similarities to and differences from IKBα. J Biol Chem 1997;272:9942-9.
48. Kammer GM, Stein RL. T lymphocyte immune dysfunctions in systemic lupus erythematosus. J Lab Clin Med 1990;115:273-82.
49. Alcocer-Varela J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
50. Linker-Israeli M, Bakke AC. Kitridou RC. Gendler S. Gillis S, Horwitz DA. Defective production of inlerleukin l and interleukin 2 in patients with systemic lupus erythematosus. J Immunol 1983;130:2651-5.
51. Miyasaka N, Nakamura T, Russell IJ. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1984;31:109-17.
52. Murakawa Y, Takada S, Ueda Y, Suzuki N. Hoshino T. Sakane T. Characterization of the T lymphocyte subpopulations responsible for deficient IL-2 activity in patients with systemic lupus erythematosus. J Immunol 1985;134:187-95.
53. Huang Y-P, Miescher PA, Zubler RH. The interleukin 2 secretion detect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986;137:3515-20.
54. Murakawa Y. Sakane T. Deficient phytohemagglutin induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1988;31:826-33.
55. Ghosh P, Tan TH. Rice NR, Sica A. Young HA. The interleukin 2 CD28-responsive complex contains at least three members of the NF-KB family: c-Rel, p50, and p65. Proc Natl Acad Sci USA 1993;90:1696-700.
56. Scheinman RI. Cogswell PC. Lofquist AK. Baldwin AS Role of transcriptional activation of IKBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
57. Auphan N. DiDonato JA. Rosette C. Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NK-KB activity through induction of IKB synthesis. Science 1995; 270:286-90.
58. Chiao PJS, Miyamoto S, Verma IM. Autoregulation of IKB-α activity. Proc Natl Acad Sci USA 1994;91:28-32.
59. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S. Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus crythematosus and rheumatoid arthritis. Arthritis Rheum 1990;33:1665-73.
60. Yung RL, Richardson BC. Role of T cell DNA methylation in lupus syndrome. Lupus 1994;3:487-91.
61. Yung RL, Johnson KJ. Richardson BC. Biology of disease: New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995;73:746-59.
62. Tada Y. Nagasawa K. Yamauchi Y. Tsukamoto H. Niho Y. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1991;60:220-31.
63. Ghosh S, May MJ, Kopp EB. NF-KB and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
64. Linker-Israeli M, Deans R. Dysregulated lymphokine production in systemic lupus erythematosus. Ann NY Acad Sci 1989;557:567-9.
65. Horwitz DA. Wang H. Gray D. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA. Lupus 1994;3:423-8.
66. Vaishnaw AK, McNally JD, Elkon KB. Apoptosis in the rheumatic diseases. Athritis Rheum 1997;40:1917-27.
67. Kruisbeek A. Amsen D. Mechanisms underlying T-cell tolerance. Curr Opin Immunol 1996;8:233-44.